289 related articles for article (PubMed ID: 19696041)
1. Dabigatran etexilate for the prophylaxis of venous thromboembolism after hip or knee replacement rationale for dose regimen.
Dahl OE
Clin Appl Thromb Hemost; 2009; 15 Suppl 1():17S-24S. PubMed ID: 19696041
[TBL] [Abstract][Full Text] [Related]
2. Dabigatran etexilate: pivotal trials for venous thromboembolism prophylaxis after hip or knee arthroplasty.
Eriksson BI; Friedman RJ
Clin Appl Thromb Hemost; 2009; 15 Suppl 1():25S-31S. PubMed ID: 19648146
[TBL] [Abstract][Full Text] [Related]
3. Dabigatran etexilate: future directions in anticoagulant treatment.
Schulman S; Reilly PA
Clin Appl Thromb Hemost; 2009; 15 Suppl 1():32S-41S. PubMed ID: 19679590
[TBL] [Abstract][Full Text] [Related]
4. Oral antithrombotic inhibitors: dabigatran etexilate, meeting an unmet need?
Hull R
Clin Appl Thromb Hemost; 2009; 15 Suppl 1():5S-8S. PubMed ID: 19706619
[TBL] [Abstract][Full Text] [Related]
5. Pharmacology, pharmacokinetics, and pharmacodynamics of dabigatran etexilate, an oral direct thrombin inhibitor.
Stangier J; Clemens A
Clin Appl Thromb Hemost; 2009; 15 Suppl 1():9S-16S. PubMed ID: 19696042
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of dabigatran etexilate for the prevention of venous thromboembolism following total hip or knee arthroplasty. A meta-analysis.
Wolowacz SE; Roskell NS; Plumb JM; Caprini JA; Eriksson BI
Thromb Haemost; 2009 Jan; 101(1):77-85. PubMed ID: 19132192
[TBL] [Abstract][Full Text] [Related]
7. Dabigatran etexilate for prevention of venous thromboembolism.
Eikelboom JE; Weitz JI
Thromb Haemost; 2009 Jan; 101(1):2-4. PubMed ID: 19132179
[No Abstract] [Full Text] [Related]
8. Dabigatran versus enoxaparin for prevention of venous thromboembolism after hip or knee arthroplasty: a pooled analysis of three trials.
Friedman RJ; Dahl OE; Rosencher N; Caprini JA; Kurth AA; Francis CW; Clemens A; Hantel S; Schnee JM; Eriksson BI;
Thromb Res; 2010 Sep; 126(3):175-82. PubMed ID: 20434759
[TBL] [Abstract][Full Text] [Related]
9. Dabigatran: new drug. Continue to use heparin, a better-known option.
Prescrire Int; 2009 Jun; 18(101):97-9. PubMed ID: 19637411
[TBL] [Abstract][Full Text] [Related]
10. Oral thrombin inhibitor dabigatran etexilate vs North American enoxaparin regimen for prevention of venous thromboembolism after knee arthroplasty surgery.
; Ginsberg JS; Davidson BL; Comp PC; Francis CW; Friedman RJ; Huo MH; Lieberman JR; Muntz JE; Raskob GE; Clements ML; Hantel S; Schnee JM; Caprini JA
J Arthroplasty; 2009 Jan; 24(1):1-9. PubMed ID: 18534438
[TBL] [Abstract][Full Text] [Related]
11. Economic evaluation of dabigatran etexilate for the prevention of venous thromboembolism after total knee and hip replacement surgery.
Wolowacz SE; Roskell NS; Maciver F; Beard SM; Robinson PA; Plumb JM; Dolan G; Brenkel IJ
Clin Ther; 2009 Jan; 31(1):194-212. PubMed ID: 19243718
[TBL] [Abstract][Full Text] [Related]
12. Dabigatran etexilate--a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity.
van Ryn J; Stangier J; Haertter S; Liesenfeld KH; Wienen W; Feuring M; Clemens A
Thromb Haemost; 2010 Jun; 103(6):1116-27. PubMed ID: 20352166
[TBL] [Abstract][Full Text] [Related]
13. Dabigatran etexilate: an oral direct thrombin inhibitor for prophylaxis and treatment of thromboembolic diseases.
Baetz BE; Spinler SA
Pharmacotherapy; 2008 Nov; 28(11):1354-73. PubMed ID: 18956996
[TBL] [Abstract][Full Text] [Related]
14. Rivaroxaban and dabigatran etexilate: two new oral anticoagulants for extended postoperative prevention of venous thromboembolism after elective total hip arthroplasty.
Borris LC
Arch Orthop Trauma Surg; 2010 May; 130(5):583-9. PubMed ID: 19565250
[TBL] [Abstract][Full Text] [Related]
15. Thromboembolic prophylaxis in orthopedic surgery using dabigatran: an oral direct thrombin inhibitor.
Garza R; Huo MH
Expert Rev Cardiovasc Ther; 2012 Apr; 10(4):423-7. PubMed ID: 22458575
[TBL] [Abstract][Full Text] [Related]
16. Dabigatran vs. low molecular weight heparin in preventing venous thromboembolism after elective hip and knee arthroplasty: evaluation of selected clinical parameters.
Mrozik D; Jackiewicz A; Krzemiński M
Pol Orthop Traumatol; 2012 Oct; 77():111-4. PubMed ID: 23306297
[TBL] [Abstract][Full Text] [Related]
17. Dabigatran etexilate: a review of its use for the prevention of venous thromboembolism after total hip or knee replacement surgery.
Burness CB; McKeage K
Drugs; 2012 May; 72(7):963-86. PubMed ID: 22564134
[TBL] [Abstract][Full Text] [Related]
18. Enoxaparin versus dabigatran or rivaroxaban for thromboprophylaxis after hip or knee arthroplasty: Results of separate pooled analyses of phase III multicenter randomized trials.
Huisman MV; Quinlan DJ; Dahl OE; Schulman S
Circ Cardiovasc Qual Outcomes; 2010 Nov; 3(6):652-60. PubMed ID: 20923996
[TBL] [Abstract][Full Text] [Related]
19. Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial.
Eriksson BI; Dahl OE; Rosencher N; Kurth AA; van Dijk CN; Frostick SP; Prins MH; Hettiarachchi R; Hantel S; Schnee J; Büller HR;
Lancet; 2007 Sep; 370(9591):949-56. PubMed ID: 17869635
[TBL] [Abstract][Full Text] [Related]
20. Dabigatran etexilate versus warfarin as the oral anticoagulant of choice? A review of clinical data.
Ma TK; Yan BP; Lam YY
Pharmacol Ther; 2011 Feb; 129(2):185-94. PubMed ID: 20920530
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
